# Dewpoint Therapeutics

> Dewpoint Therapeutics is a Boston biotechnology company developing small molecules that alter biomolecular condensates, the membraneless compartments that organize cellular activity. Its lead candidate, DPTX3186, is being tested in advanced solid tumors with a focus on gastric cancer; other programs address MYC-driven cancers, ALS, heart disease and insulin resistance. It combines proprietary discovery with pharmaceutical research and licensing partnerships.

- **Founded:** 2018
- **Headquarters:** Boston, United States
- **Founders:** Anthony Hyman (Scientific co-founder), Richard Young (Scientific co-founder)
- **Products:** DPTX3186, MYC condensate modulator, TDP-43 condensate modulator, Condensate discovery platform / ERSAi, Dilated cardiomyopathy program
- **Notable:** DPTX3186 first-patient dosing announced February 2026., DPTX3186 received FDA Orphan Drug and Fast Track designations for gastric cancer in 2025, according to company announcements; neither is marketing approval., Bayer exercised its dilated cardiomyopathy license option in October 2024.

## Products & services

- **DPTX3186** — Investigational oral beta-catenin condensate modulator for Wnt-driven cancers; first patient dosing announced February 4, 2026. Company describes the study as Phase 1a/2a; registry NCT07312903 classifies it as Phase 1.
- **MYC condensate modulator** — Small-molecule oncology development candidate selected February 2026; preclinical tumor-model data presented at AACR in April 2026.
- **TDP-43 condensate modulator** — Preclinical development candidate selected January 2026 for ALS and related neurodegenerative disorders; designed to restore TDP-43 function by correcting pathological condensates.
- **Condensate discovery platform / ERSAi** — Proprietary platform joining cellular models, automated high-content imaging, chemistry and computational analysis to identify and optimize condensate-modulating compounds. Not established as a publicly purchasable software product.
- **Dilated cardiomyopathy program** — Program for a genetically defined form of dilated cardiomyopathy licensed globally to Bayer in October 2024.
- **Insulin resistance discovery programs** — Research programs with Novo Nordisk to discover therapies targeting condensates involved in insulin resistance and diabetic complications.
- **Viral condensate phenomics atlas for HPV** — Gates Foundation-funded research initiative announced January 2026; Dewpoint commits to sharing generated data openly.

## Achievements

- DPTX3186 first-patient dosing announced February 2026.
- DPTX3186 received FDA Orphan Drug and Fast Track designations for gastric cancer in 2025, according to company announcements; neither is marketing approval.
- Bayer exercised its dilated cardiomyopathy license option in October 2024.
- Selected TDP-43 and MYC development candidates in January and February 2026 respectively.
- Raised US$287 million across disclosed Series A-C rounds before a later undisclosed Series D.

## Latest updates

- **2026-05** — Presented DPTX3186 trial-design poster at the ASCO Annual Meeting; listed on the company science page.
- **2026-04** — Reported preclinical oral MYC condensate-modulator data at AACR.
- **2026-02** — Selected MYC development candidate and announced first-patient dosing for DPTX3186.
- **2026-01** — Selected TDP-43 development candidate and announced Gates-funded HPV atlas initiative.
- **2025-09** — Closed Series D of undisclosed size, with stated operational runway into early 2027.

## Links

- Website: https://dewpointx.com/
- LinkedIn: https://www.linkedin.com/company/dewpointtherapeutics/
- Twitter/X: https://twitter.com/dewpoint_tx
- Facebook: https://www.facebook.com/dewpointtherapeutics

---

Profile page: https://yespress.io/dewpoint-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-10-04